Article Text

Download PDFPDF
Use of conjugate pneumococcal vaccine by United Kingdom neonatal intensive care units
  1. S J Moss1,
  2. A C Fenton1,
  3. A R Gennery2
  1. 1Ward 35, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, UK
  2. 2School of Clinical Medical sciences (Child Health), Newcastle General Hospital, West Road, Newcastle upon Tyne NE4 6BE, UK
  1. Correspondence to:
    Dr Moss
    Neonatal Research Fellow, Ward 35, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne NE1 4LP;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Although the polysaccharide pneumococcal vaccine is ineffective in children less than 2 years of age,1 the conjugate pneumococcal vaccine, Prevenar, has been shown to be protective.2

In 2002, the Chief Medical Officer advised that children under 2 years of age at risk of invasive pneumococcal disease should receive three doses of Prevenar with their primary immunisations followed by a booster in the second year of life.3 Many of these infants start their immunisations on neonatal units. In our centre, infants complete their primary course, but …

View Full Text


  • Competing interests: none declared